

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1) (currently amended) Peptide having the following primary structure:

Asp-Pro-His-~~L~~Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

2) (currently amended) Peptide having sequence-identity of at least 60% with the following sequence:

Asp-Pro-His--~~L~~Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

3) (currently amended) Peptide having electric-charge homology or hydrophilia or hydrophobicity or solvent-exposure rate or three-dimensional conformation of at least 60% with the following sequence:

Asp-Pro-His--~~L~~Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

4) (currently amended) Peptidic or non-peptidic molecules showing conformational similarity or functional-group disposition similarity, of at least 60% with the following sequence:

Asp-Pro-His--~~L~~Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

5. (previously presented) The use of the peptides of claim 1 as inhibitors of platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF).

6. (previously presented) The use of the peptides of claim 1 for the preparation of a pharmacological compound able to affect cell proliferation.

7. (previously presented) The use of the peptides of claim 1 for the preparation of a pharmacological compound able to affect cell migration and tumor cell migration toward potential metastatic sites.

8. (previously presented) The use of the peptides of claim 1 as inhibitors of primary tumor growth and metastasis.

9. (previously presented) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used as adjuvant for the treatment of neoplastic and vascular diseases.

10. (previously presented) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used for the treatment of vascular diseases.

11. (previously presented) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used for the treatment of thrombotic events and related pathologies.